Gefitinib Radiosensitizes Non–Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity

Purpose: Overexpression of the epidermal growth factor receptor (EGFR) promotes unregulated growth, inhibits apoptosis, and likely contributes to clinical radiation resistance of non–small cell lung cancer (NSCLC). Molecular blockade of EGFR signaling is an attractive therapeutic strategy for enhancing the cytotoxic effects of radiotherapy that is currently under investigation in preclinical and clinical studies. In the present study, we have investigated the mechanism by which gefitinib, a selective EGFR tyrosine kinase inhibitor, restores the radiosensitivity of NSCLC cells. Experimental Design: Two NSCLC cell lines, A549 and H1299, were treated with 1 μmol/L gefitinib for 24 h before irradiation and then tested for clonogenic survival and capacity for repairing DNA double strand breaks (DSB). Four different repair assays were used: host cell reactivation, detection of γ-H2AX and pNBS1 repair foci using immunofluorescence microscopy, the neutral comet assay, and pulsed-field gel electrophoresis. Results: In clonogenic survival experiments, gefitinib had significant radiosensitizing effects on both cell lines. Results from all four DNA damage repair analyses in cultured A549 and H1299 cells showed that gefitinib had a strong inhibitory effect on the repair of DSBs after ionizing radiation. The presence of DSBs was especially prolonged during the first 2 h of repair compared with controls. Immunoblot analysis of selected repair proteins indicated that pNBS1 activation was prolonged by gefitinib correlating with its effect on pNBS1-labeled repair foci. Conclusions: Overall, we conclude that gefitinib enhances the radioresponse of NSCLC cells by suppressing cellular DNA repair capacity, thereby prolonging the presence of radiation-induced DSBs.

[1]  P. Dent,et al.  Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. , 2002, Molecular biology of the cell.

[2]  S. Varambally,et al.  Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. , 2006, Cancer research.

[3]  R. Mirzayans,et al.  Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: implications for evaluation of clinical radiosensitivity. , 2006, International journal of radiation oncology, biology, physics.

[4]  P. Olive,et al.  DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. , 1991, Cancer research.

[5]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[6]  Shaomeng Wang,et al.  Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair , 2006, Clinical Cancer Research.

[7]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[8]  P. Harari,et al.  Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). , 2002, Cancer research.

[9]  K. Gibson,et al.  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.

[10]  R. Herbst,et al.  Targeting the epidermal growth factor receptor in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Kris,et al.  ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Kris,et al.  The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Trivett,et al.  EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. , 2003, International journal of radiation oncology, biology, physics.

[14]  G. Tortora,et al.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Paul Dent,et al.  MAPK pathways in radiation responses , 2003, Oncogene.

[16]  G. Fontanini,et al.  Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[18]  A. Ashworth,et al.  Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment , 2006, Molecular Cancer Therapeutics.

[19]  S. Varambally,et al.  Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). , 2005, Cancer research.

[20]  N. Magné,et al.  Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil , 2003, British Journal of Cancer.

[21]  M. Suntharalingam,et al.  Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein. , 2007, International journal of radiation oncology, biology, physics.

[22]  M. Story,et al.  Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells , 2004, Oncogene.

[23]  David J. Chen,et al.  Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.

[24]  K. Dittmann,et al.  Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  P. Dent,et al.  Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. , 2007, Cancer research.

[26]  P. Tofilon,et al.  Pulsed-field gel electrophoretic analysis of DNA double-strand breaks in mammalian cells using photostimulable storage phosphor imaging. , 1994, International journal of radiation biology.

[27]  P. Harari,et al.  Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[29]  K. Nakashiro,et al.  Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer , 2003, International journal of cancer.

[30]  P. Olive,et al.  Radiation Sensitivity, H2AX Phosphorylation, and Kinetics of Repair of DNA Strand Breaks in Irradiated Cervical Cancer Cell Lines , 2004, Cancer Research.

[31]  K. Valerie,et al.  Host-cell reactivation of reporter genes introduced into cells by adenovirus as a convenient way to measure cellular DNA repair. , 1995, Mutation research.

[32]  Rick Chappell,et al.  Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. , 2004, International journal of radiation oncology, biology, physics.

[33]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[34]  J. Ochs.  Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. , 2004, International journal of radiation oncology, biology, physics.

[35]  S. Tucker,et al.  Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity , 2005, Clinical Cancer Research.